Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 HKD | +2.56% | +3.45% | +14.29% |
03-26 | Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024 | CI |
03-25 | Dawnrays' 2023 Profit Falls 9% on Lower Revenue | MT |
Sales 2022 | 1.28B 176M 1.38B 14.08B | Sales 2023 | 1.15B 159M 1.24B 12.69B | Capitalization | 1.43B 198M 1.55B 15.78B |
---|---|---|---|---|---|
Net income 2022 | 358M 49.41M 387M 3.95B | Net income 2023 | 326M 44.99M 352M 3.59B | EV / Sales 2022 | 0.54 x |
Net cash position 2022 | 1.07B 148M 1.16B 11.83B | Net cash position 2023 | 1.05B 145M 1.14B 11.61B | EV / Sales 2023 | 0.33 x |
P/E ratio 2022 |
4.93
x | P/E ratio 2023 |
4.4
x | Employees | 1,143 |
Yield 2022 |
6.63% | Yield 2023 |
7.61% | Free-Float | 39.97% |
1 day | +2.56% | ||
1 week | +3.45% | ||
Current month | +2.56% | ||
1 month | +1.69% | ||
3 months | +9.09% | ||
6 months | +10.09% | ||
Current year | +14.29% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Xian Wu
CEO | Chief Executive Officer | 55 | 15/02/22 |
Yi jun Wu
DFI | Director of Finance/CFO | 59 | 30/11/02 |
Kei Ling Li
CHM | Chairman | 75 | 30/09/02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kei Ling Li
CHM | Chairman | 75 | 30/09/02 |
Yung Lai Hung
BRD | Director/Board Member | 79 | 30/09/02 |
Hong Man Leung
BRD | Director/Board Member | 49 | 31/10/05 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 1.2 | +2.56% | 60 000 |
26/04/24 | 1.17 | 0.00% | 40,000 |
25/04/24 | 1.17 | 0.00% | 0 |
24/04/24 | 1.17 | -1.68% | 144,000 |
23/04/24 | 1.19 | +2.59% | 112,000 |
Delayed Quote Hong Kong S.E., April 29, 2024 at 04:11 am
More quotes1st Jan change | Capi. | |
---|---|---|
+14.29% | 224M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 2348 Stock